CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Launxp Biomedical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Launxp Biomedical Co Ltd
Phone: +886 423205691p:+886 423205691 TAICHUNG, 408  Taiwan Ticker: 68766876
Business Summary
Launxp Biomedical Co Ltd is a Taiwan-based company mainly engaged in the development of new drugs. The Company mainly develops cancer drugs. The main products include LXPA1788, LXPA1988, LXPA5948, LXPB5268, LXPB5101, LXPB8101, LXPB9568, LXPB977 and others. LXPA1788 is a new ingredient and new drug, a multi-target kinase inhibitor. LXPA1988 is a new ingredient and new drug with a novel chemical structure. It exhibits high inhibitory activity against the fms-like tyrosine kinase 3 (FLT3) kinase and its mutations, inhibiting FLT3 signaling in acute myeloid leukemia (AML) cancer cells and thereby inhibiting tumor growth. LXPA5948 is a new ingredient and new drug. LXPB5268 is a new drug for new indications. LXPB5101, LXPB8101, LXPB9568, and LXPB977 are new drugs with new indications and new dosage forms.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Head of Finance ShifengYan 4/16/2023 4/16/2023

General Information
Outstanding Shares: 32,189,000 (As of 6/30/2024)
Stock Exchange: TPO
Fax Number: +886 423205693


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024